MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,687.00
+4.00 (0.24%)
At close: Dec 9, 2025
45.18%
Market Cap65.88B
Revenue (ttm)9.80B
Net Income (ttm)-11.86B
Shares Out39.05M
EPS (ttm)-339.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume337,233
Average Volume414,346
Open1,710.00
Previous Close1,683.00
Day's Range1,661.00 - 1,710.00
52-Week Range999.00 - 2,250.00
Beta1.39
RSI49.94
Earnings DateNov 11, 2025

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.